| 2333 | Humans |
| 1192 | Female |
| 1110 | Antibodies, Monoclonal, Humanized (therapeutic use) |
| 1028 | Male |
| 965 | Arthritis, Rheumatoid (drug therapy) |
| 848 | Middle Aged |
| 822 | Treatment Outcome |
| 798 | Antirheumatic Agents (therapeutic use) |
| 687 | Adult |
| 573 | Aged |
| 404 | Antibodies, Monoclonal (therapeutic use) |
| 358 | Antibodies, Monoclonal, Humanized (adverse effects) |
| 322 | Antibodies, Monoclonal, Humanized |
| 317 | Antirheumatic Agents (adverse effects) |
| 310 | Antibodies, Monoclonal, Humanized (administration & dosage) |
| 306 | Receptors, Interleukin-6 (antagonists & inhibitors) |
| 269 | Rheumatoid arthritis |
| 268 | Animals |
| 265 | Tumor Necrosis Factor-alpha (antagonists & inhibitors) |
| 248 | Drug Therapy, Combination |
| 234 | Severity of Illness Index |
| 224 | Tocilizumab |
| 216 | Methotrexate (therapeutic use) |
| 212 | Interleukin-6 (antagonists & inhibitors) |
| 203 | Biological Products (therapeutic use) |
| 197 | Antirheumatic Agents (administration & dosage) |
| 186 | Antibodies, Monoclonal, Humanized (pharmacology) |
| 183 | Retrospective Studies |
| 182 | Child |
| 182 | Adolescent |
| 178 | Chronic |
| 176 | Immunosuppressive Agents (therapeutic use) |
| 175 | Receptors, Interleukin-6 (immunology) |
| 169 | Young Adult |
| 167 | Arthritis, Rheumatoid (immunology) |
| 165 | Immunomodulator |
| 164 | Rheumatology |
| 151 | Remission Induction |
| 149 | Interleukin-6 (metabolism) |
| 145 | Time Factors |
| 141 | Arthritis, Juvenile (drug therapy) |
| 130 | Treatment |
| 127 | Antibodies, Monoclonal (adverse effects) |
| 126 | Glucocorticoids (therapeutic use) |
| 123 | Arthritis, Rheumatoid (blood) |
| 119 | Arthritis, Rheumatoid (diagnosis) |
| 112 | Interleukin-6 (immunology) |
| 111 | Follow-Up Studies |
| 111 | Arthritis, Rheumatoid (complications) |
| 105 | Rituximab |
| 103 | Human |
| 102 | Randomized Controlled Trials as Topic |
| 102 | Prospective Studies |
| 100 | Double-Blind Method |
| 95 | Disease Progression |
| 95 | Aged, 80 and over |
| 93 | Immunosuppressive agent |
| 91 | Interleukin 6 |
| 91 | Child, Preschool |
| 90 | Giant Cell Arteritis (drug therapy) |
| 90 | Biological Products (adverse effects) |
| 89 | Mice |
| 89 | Abatacept (therapeutic use) |
| 88 | Infliximab |
| 87 | Risk Factors |
| 87 | Biomarkers (blood) |
| 85 | Clinical Trials as Topic |
| 85 | Abatacept |
| 83 | Drug Administration Schedule |
| 81 | Prognosis |
| 80 | Adalimumab |
| 79 | Etanercept |
| 77 | Rituximab (therapeutic use) |
| 76 | Dose-Response Relationship, Drug |
| 74 | Interleukin-6 (blood) |
| 73 | Receptors, Interleukin-6 (metabolism) |
| 73 | Antibodies, Monoclonal (administration & dosage) |
| 72 | Arthritis, Rheumatoid (physiopathology) |
| 71 | Antibodies, Monoclonal (pharmacology) |
| 70 | Castleman Disease (drug therapy) |
| 68 | Anti-Inflammatory Agents (therapeutic use) |
| 67 | Registries |
| 66 | Methotrexate (administration & dosage) |
| 66 | Japan |
| 65 | Still's Disease, Adult-Onset (drug therapy) |
| 64 | Takayasu Arteritis (drug therapy) |
| 64 | Signal Transduction (drug effects) |
| 62 | Antirheumatic Agents (pharmacology) |
| 61 | Recurrence |
| 61 | Etanercept (therapeutic use) |
| 60 | Cohort Studies |
| 59 | Immunologic Factors (therapeutic use) |
| 58 | Immunoconjugates (therapeutic use) |
| 58 | Arthritis, Rheumatoid (pathology) |
| 57 | Arthritis, Rheumatoid (metabolism) |
| 56 | Infliximab (therapeutic use) |
| 55 | Arthritis, Rheumatoid (therapy) |
| 53 | Interleukin 1 Receptor Antagonist Protein (therapeutic use) |
| 52 | Interleukin-6 (physiology) |
| 52 | Drug Resistance |
| 52 | Adalimumab (therapeutic use) |
| 51 | Treatment Failure |
| 51 | Diagnosis, Differential |
| 51 | Adrenal Cortex Hormones (therapeutic use) |
| 50 | Immunoglobulin G (therapeutic use) |
| 49 | Receptors, Tumor Necrosis Factor (therapeutic use) |
| 47 | Tomography, X-Ray Computed |
| 47 | Arthritis, Rheumatoid (diagnostic imaging) |
| 47 | Antirheumatic agent |
| 46 | Biological Factors (therapeutic use) |
| 45 | Infusions, Intravenous |
| 44 | Glucocorticoids (administration & dosage) |
| 44 | Cell Line, Tumor |
| 43 | Incidence |
| 43 | C-Reactive Protein (metabolism) |
| 43 | Antibodies, Monoclonal, Humanized (immunology) |
| 42 | Rheumatic Diseases (drug therapy) |
| 42 | Cytokines (metabolism) |
| 42 | Arthritis, Rheumatoid (epidemiology) |
| 41 | Molecular Targeted Therapy |
| 40 | Interleukin-6 (genetics) |
| 40 | Inflammation |
| 40 | Inflammation (drug therapy) |
| 40 | Antibodies, Monoclonal, Murine-Derived (therapeutic use) |
| 39 | Immunosuppressive Agents (adverse effects) |
| 39 | Disease Models, Animal |
| 39 | Biopsy |
| 38 | Risk Assessment |
| 38 | Predictive Value of Tests |
| 38 | Injections, Subcutaneous |
| 38 | Biological Products (administration & dosage) |
| 37 | Quality of Life |
| 37 | Magnetic Resonance Imaging |
| 36 | Radiography |
| 36 | Prednisone (therapeutic use) |
| 36 | Arthritis, Juvenile (immunology) |
| 36 | Antirheumatic Agents (economics) |
| 35 | Syndrome |
| 35 | Interleukin-6 |
| 35 | Drug Substitution |
| 35 | Case-Control Studies |
| 35 | Amyloidosis (drug therapy) |
| 34 | Toxicity |
| 34 | Signal Transduction |
| 34 | Methotrexate (adverse effects) |
| 34 | Immunosuppressive Agents (administration & dosage) |
| 34 | Chronic Disease |
| 33 | Uveitis (drug therapy) |
| 33 | Immunotherapy (methods) |
| 32 | STAT3 Transcription Factor (metabolism) |
| 32 | Polymyalgia Rheumatica (drug therapy) |
| 32 | Methotrexate |
| 32 | Castleman Disease (complications) |
| 32 | C-Reactive Protein (analysis) |
| 32 | Biological Therapy |
| 32 | Biological Therapy (methods) |
| 32 | Antibodies, Monoclonal (immunology) |
| 31 | United States |
| 31 | Inflammation (immunology) |
| 31 | Blood Sedimentation |
| 30 | Pregnancy |
| 30 | Biotherapy |
| 30 | Antibodies, Monoclonal, Humanized (pharmacokinetics) |
| 29 | Arthritis, Juvenile (complications) |
| 28 | Tumor Necrosis Factor-alpha (metabolism) |
| 28 | Tumor Necrosis Factor-alpha (immunology) |
| 28 | T-Lymphocytes (immunology) |
| 28 | Arthritis, Rheumatoid (economics) |
| 28 | Antineoplastic agent |
| 27 | Cost-Benefit Analysis |
| 27 | Cell Proliferation (drug effects) |
| 27 | Castleman Disease (diagnosis) |
| 27 | Behcet Syndrome (drug therapy) |
| 27 | Arthritis, Rheumatoid (genetics) |
| 27 | Anti-Inflammatory Agents, Non-Steroidal (therapeutic use) |
| 26 | Review |
| 26 | Giant Cell Arteritis (diagnosis) |
| 26 | Disease Management |
| 26 | Cells, Cultured |
| 26 | Autoimmune Diseases (drug therapy) |
| 26 | Antibodies, Monoclonal, Murine-Derived |
| 25 | Spondylitis, Ankylosing (drug therapy) |
| 25 | Proportional Hazards Models |
| 25 | Pilot Projects |
| 25 | Infant |
| 25 | Glucocorticoids (adverse effects) |
| 25 | Arthritis, Psoriatic (drug therapy) |
| 25 | Arthritis, Juvenile (diagnosis) |
| 24 | Pyrimidines (therapeutic use) |
| 24 | Immunocompromised Host |
| 24 | Antibodies, Monoclonal, Humanized (economics) |
| 23 | Pyrroles (therapeutic use) |
| 23 | Phenotype |
| 23 | Joints (pathology) |
| 23 | Drug Design |
| 23 | Biologics |
| 23 | Antirheumatic Agents (pharmacokinetics) |
| 22 | Scleroderma, Systemic (drug therapy) |
| 22 | Remission Induction (methods) |
| 22 | Receptors, Interleukin-6 (blood) |
| 22 | Practice Guidelines as Topic |
| 22 | Polychondritis, Relapsing (drug therapy) |
| 22 | Piperidines (therapeutic use) |
| 22 | Mice, Inbred C57BL |
| 22 | Kaplan-Meier Estimate |
| 22 | Immunotherapy |
| 22 | Cytokines (immunology) |
| 22 | Cytokines (blood) |
| 21 | Takayasu Arteritis (diagnosis) |
| 21 | Still's Disease, Adult-Onset (complications) |
| 21 | Receptors, Interleukin-6 (genetics) |
| 21 | Prednisone (administration & dosage) |
| 21 | Prednisolone (therapeutic use) |
| 21 | Neuromyelitis Optica (drug therapy) |
| 21 | Longitudinal Studies |
| 21 | Interleukin-6 (pharmacology) |
| 21 | Immunotherapy, Adoptive (adverse effects) |
| 21 | Certolizumab Pegol (therapeutic use) |
| 20 | Xenograft Model Antitumor Assays |
| 20 | Surveys and Questionnaires |
| 20 | Signal Transduction (immunology) |
| 20 | Joints (drug effects) |
| 20 | IL-6 |
| 20 | Health Status |
| 20 | Enzyme-Linked Immunosorbent Assay |
| 20 | Combined Modality Therapy |
| 19 | Risk |
| 19 | Lupus Erythematosus, Systemic (drug therapy) |
| 19 | Immunologic Factors (adverse effects) |
| 19 | Immunoglobulin G (adverse effects) |
| 19 | Graves Ophthalmopathy (drug therapy) |
| 19 | Drug Monitoring (methods) |
| 19 | Comorbidity |
| 19 | Biomarkers (metabolism) |
| 19 | Arthritis, Rheumatoid (etiology) |
| 19 | Arthritis (drug therapy) |
| 19 | Antirheumatic Agents (immunology) |
| 18 | Rituximab (adverse effects) |
| 18 | Retreatment |
| 18 | Rats |
| 18 | Prednisolone (administration & dosage) |
| 18 | Juvenile rheumatoid arthritis |
| 18 | Immunohistochemistry |
| 18 | Databases, Factual |
| 18 | Cytokine |
| 18 | Castleman Disease (pathology) |
| 18 | Arthritis, Juvenile (therapy) |
| 18 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 18 | Antibodies, Monoclonal (pharmacokinetics) |
| 18 | Amyloidosis (etiology) |
| 17 | Still's Disease, Adult-Onset (diagnosis) |
| 17 | Positron-Emission Tomography |
| 17 | Models, Biological |
| 17 | Injections, Intravenous |
| 17 | Inflammation Mediators (blood) |
| 17 | Evidence-Based Medicine |
| 17 | Cytokines (antagonists & inhibitors) |
| 17 | Cyclosporine (therapeutic use) |
| 17 | Cyclophosphamide (therapeutic use) |
| 17 | B-Lymphocytes (immunology) |
| 17 | Autoimmune Diseases (immunology) |
| 17 | Arthritis, Juvenile (physiopathology) |
| 17 | Anti-Tumor Necrosis Factor-alpha |
| 16 | Withholding Treatment |
| 16 | Outcome Assessment, Health Care |
| 16 | Opportunistic Infections (chemically induced) |
| 16 | Monoclonal antibody |
| 16 | Medicine |
| 16 | Matrix Metalloproteinase 3 (blood) |
| 16 | Logistic Models |
| 16 | Leflunomide |
| 16 | Infections (etiology) |
| 16 | Immunotherapy, Adoptive (methods) |
| 16 | Etanercept (adverse effects) |
| 16 | Disability Evaluation |
| 16 | Cytokines |
| 16 | Cross-Sectional Studies |
| 16 | Clinical Trials, Phase III as Topic |
| 16 | Biological receptor |
| 16 | Algorithms |
| 16 | Abatacept (adverse effects) |
| 15 | Vasculitis |
| 15 | Tumor necrosis factor |
| 15 | Tumor Necrosis Factor-alpha (therapeutic use) |
| 15 | Tomography, Optical Coherence |
| 15 | Spondylarthritis (drug therapy) |
| 15 | Signal Transduction (physiology) |
| 15 | Serum Amyloid A Protein (metabolism) |
| 15 | Network Meta-Analysis |
| 15 | Multivariate Analysis |
| 15 | Methylprednisolone (therapeutic use) |
| 15 | Juvenile idiopathic arthritis |
| 15 | Joints (physiopathology) |
| 15 | Interleukin-1 (antagonists & inhibitors) |
| 15 | Drug Interactions |
| 15 | Biomarkers |
| 15 | Biomarkers (analysis) |
| 15 | Arthritis |
| 15 | Antigens, CD19 (immunology) |
| 15 | Anti-TNF |
| 14 | Takayasu Arteritis (therapy) |
| 14 | T-Lymphocytes, Regulatory (immunology) |
| 14 | Steroids (therapeutic use) |
| 14 | Skin (pathology) |
| 14 | Psoriasis (drug therapy) |
| 14 | Odds Ratio |
| 14 | Molecular Targeted Therapy (methods) |
| 14 | Immunoconjugates (adverse effects) |
| 14 | Glucocorticoids |
| 14 | Europe |
| 14 | Drug Eruptions (etiology) |
| 14 | Certolizumab Pegol |
| 14 | Biological Therapy (adverse effects) |
| 14 | Antiviral Agents (therapeutic use) |
| 14 | Antineoplastic Agents (pharmacology) |
| 14 | Antibody |
| 14 | Anti-Inflammatory Agents (adverse effects) |
| 14 | Anti-Bacterial Agents (therapeutic use) |
| 14 | Amyloidosis (complications) |
| 14 | Adalimumab (adverse effects) |
| 13 | tocilizumab |
| 13 | Vasculitis (drug therapy) |
| 13 | Ultrasonography |
| 13 | Therapy |
| 13 | Rheumatic Diseases (immunology) |
| 13 | Reproducibility of Results |
| 13 | Receptors, Tumor Necrosis Factor (administration & dosage) |
| 13 | Psoriasis (chemically induced) |
| 13 | Protein Kinase Inhibitors (therapeutic use) |
| 13 | Pregnancy Complications (drug therapy) |
| 13 | Polymyalgia Rheumatica (diagnosis) |
| 13 | Neoplasms (immunology) |
| 13 | Italy |
| 13 | Inflammation (pathology) |
| 13 | Inflammation (metabolism) |
| 13 | Immunosuppression |
| 13 | Immunoglobulin G (administration & dosage) |
| 13 | Graft vs Host Disease (drug therapy) |
| 13 | Germany |
| 13 | Flow Cytometry |
| 13 | Fatal Outcome |
| 13 | Drug Approval |
| 13 | Cell Proliferation |
| 13 | Cell Line |
| 13 | Castleman Disease (therapy) |
| 13 | Biological Products (economics) |
| 13 | Biological Factors (adverse effects) |
| 13 | Bibliographic review |
| 13 | Bayes Theorem |
| 13 | Apoptosis (drug effects) |
| 13 | Anti-Inflammatory Agents (pharmacology) |
| 13 | Ankylosing spondylitis |
| 13 | Administration, Intravenous |
| 12 | Vaccination |
| 12 | Tumor necrosis factor α |
| 12 | Tumor Cells, Cultured |
| 12 | Systemic lupus erythematosus |
| 12 | Synovitis (drug therapy) |
| 12 | Receptors, Antigen, T-Cell (immunology) |
| 12 | Quality-Adjusted Life Years |
| 12 | Prevalence |
| 12 | Prednisone (adverse effects) |
| 12 | Precursor Cell Lymphoblastic Leukemia-Lymphoma (therapy) |
| 12 | Polyethylene Glycols (therapeutic use) |
| 12 | Neuromyelitis Optica (immunology) |
| 12 | Mycophenolic Acid (therapeutic use) |
| 12 | Mutation |
| 12 | Mice, SCID |
| 12 | Isoxazoles (therapeutic use) |
| 12 | Inflammation Mediators (metabolism) |
| 12 | Infection |
| 12 | Immunotherapy (adverse effects) |
| 12 | Immunosuppressive Agents (pharmacology) |
| 12 | Immunologic Factors (administration & dosage) |
| 12 | Hydroxychloroquine (therapeutic use) |
| 12 | Giant cell arteritis |
| 12 | Giant Cell Arteritis (complications) |
| 12 | France |
| 12 | Fever (drug therapy) |
| 12 | Drug |
| 12 | Drug Therapy, Combination (methods) |
| 12 | Comparative study |
| 12 | Colchicine (therapeutic use) |
| 12 | Castleman disease |
| 12 | Castleman Disease (immunology) |
| 12 | Benign lymphadenopathy |
| 12 | B-Lymphocytes (drug effects) |
| 12 | Autoimmunity |
| 12 | Anti-Inflammatory Agents (administration & dosage) |
| 12 | Abatacept (administration & dosage) |
| 11 | rheumatoid arthritis |
| 11 | Uveitis (etiology) |
| 11 | Uveitis (diagnosis) |
| 11 | United States (epidemiology) |
| 11 | Takayasu Arteritis (immunology) |
| 11 | Takayasu Arteritis (complications) |
| 11 | T-Lymphocytes, Regulatory (drug effects) |
| 11 | Sensitivity and Specificity |
| 11 | Receptors, Interleukin-6 (physiology) |
| 11 | Receptors, Interleukin-6 (drug effects) |
| 11 | Polymorphism, Single Nucleotide |
| 11 | Patient Selection |
| 11 | Monocytes (metabolism) |
| 11 | Mice, Inbred BALB C |
| 11 | Methotrexate (pharmacology) |
| 11 | Leukocytes, Mononuclear (metabolism) |
| 11 | Leukocyte Count |
| 11 | Japan (epidemiology) |
| 11 | Infliximab (adverse effects) |
| 11 | Immunoglobulin Fab Fragments (therapeutic use) |
| 11 | Giant Cell Arteritis (therapy) |
| 11 | Giant Cell Arteritis (diagnostic imaging) |
| 11 | Familial Mediterranean Fever (drug therapy) |
| 11 | Cytokines (biosynthesis) |
| 11 | Crohn Disease (drug therapy) |
| 11 | Clinical trial |
| 11 | Arthritis, Rheumatoid |
| 11 | Aortitis (drug therapy) |
| 11 | Antipsoriatic agent |
| 11 | Antineoplastic Agents (therapeutic use) |
| 11 | Age of Onset |
| 11 | Age Factors |
| 10 | Thrombocytopenia (drug therapy) |
| 10 | Th17 Cells (immunology) |
| 10 | Takayasu Arteritis (diagnostic imaging) |
| 10 | T-Lymphocytes (transplantation) |
| 10 | T-Lymphocytes (drug effects) |
| 10 | STAT3 Transcription Factor (genetics) |
| 10 | Rheumatoid Factor (blood) |
| 10 | Regression Analysis |
| 10 | Refractory |
| 10 | Receptors, Antigen, T-Cell (therapeutic use) |
| 10 | Polychondritis, Relapsing (complications) |
| 10 | Pharmacovigilance |
| 10 | Pandemics |
| 10 | Off-Label Use |
| 10 | Neutrophils (drug effects) |
| 10 | Neoplasms (drug therapy) |
| 10 | Neoplasms (chemically induced) |
| 10 | Monocytes (drug effects) |
| 10 | Lymph Nodes (pathology) |
| 10 | Lipids (blood) |
| 10 | Kidney (pathology) |
| 10 | Joint |
| 10 | Interleukin 6 receptor |
| 10 | Infliximab (administration & dosage) |
| 10 | Inflammation (complications) |
| 10 | Hematology |
| 10 | Genetic Predisposition to Disease |
| 10 | Fever |
| 10 | Edema (drug therapy) |
| 10 | Contraindications |
| 10 | Cell Survival (drug effects) |
| 10 | Cell Movement (drug effects) |
| 10 | Body Mass Index |
| 10 | Behcet Syndrome (complications) |
| 10 | Azathioprine (therapeutic use) |
| 10 | Arthritis, Rheumatoid (mortality) |
| 10 | Antirheumatic Agents |
| 10 | Anti-Inflammatory Agents, Non-Steroidal (adverse effects) |
| 10 | Amyloidosis (pathology) |
| 10 | Amyloidosis (diagnosis) |
| 10 | Adrenal Cortex Hormones (adverse effects) |
| 10 | Adrenal Cortex Hormones (administration & dosage) |
| 9 | Visual Acuity |
| 9 | Visual Acuity (physiology) |
| 9 | Uveitis (complications) |
| 9 | United Kingdom |
| 9 | Treatment efficiency |
| 9 | Takayasu Arteritis (blood) |
| 9 | Synovial Membrane (metabolism) |
| 9 | Synovial Membrane (drug effects) |
| 9 | Sweden |
| 9 | Still's Disease, Adult-Onset (therapy) |
| 9 | Still's Disease, Adult-Onset (immunology) |
| 9 | Spondylitis, Ankylosing (immunology) |
| 9 | Secondary effect |
| 9 | Risk factor |
| 9 | Remission |
| 9 | Recombinant Fusion Proteins (therapeutic use) |
| 9 | Receptors, Antigen, T-Cell (metabolism) |
| 9 | Rats, Sprague-Dawley |
| 9 | RNA, Messenger (genetics) |
| 9 | Pyrroles (adverse effects) |
| 9 | Pyrimidines (adverse effects) |
| 9 | Pregnancy Outcome |
| 9 | Precursor Cell Lymphoblastic Leukemia-Lymphoma (immunology) |
| 9 | Piperidines (adverse effects) |
| 9 | Pharmacokinetics |
| 9 | Opportunistic Infections (immunology) |
| 9 | Neutropenia (chemically induced) |
| 9 | Macular Edema (drug therapy) |
| 9 | Macrophages (metabolism) |
| 9 | Macrophage Activation Syndrome (immunology) |
| 9 | Induction Chemotherapy |
| 9 | Hereditary Autoinflammatory Diseases (genetics) |
| 9 | Giant Cell Arteritis |
| 9 | Giant Cell Arteritis (pathology) |
| 9 | Gene Expression Regulation (drug effects) |
| 9 | Forecasting |
